Trial Search Results
A Study of Modified Stem Cells in Stable Ischemic Stroke
The primary purpose of the clinical study is to determine the safety of a modified stem cell SB623 when administered to chronic, stable ischemic stroke patients. A second purpose is to determine whether SB623 might improve stroke symptoms. Chronic, stable ischemic stroke patients must be between 6 and 60 months after their stroke, and with only this one prior stroke, and and with no further improvement from physical therapy.
Stanford is currently not accepting patients for this trial.
- Biological: SB623
Phase 1/Phase 2
- Documented history of one completed ischemic stroke in subcortical region of MCA or
lenticulostriate artery with or without cortical involvement
- Between 6 and 60 months post-stroke, and having a motor neurological deficit
- No significant further improvement with physical therapy/rehabilitation
- Able and willing to undergo computed tomography (CT), magnetic resonance imaging
(MRI), and positron-emission tomography (PET) scans of the head
- History of more than 1 symptomatic stroke
- History of seizures
- History or presence of any other major neurological disease
- Myocardial infarction within prior 6 mos.
- Known presence of any malignancy except squamous or basal cell carcinoma of the skin
- Participation in any other investigational trial within 4 weeks of initial screening
and within 7 weeks of study entry
- Contraindications to head CT, MRI, or PET
- Pregnant or lactating
Ages Eligible for Study
18 Years - 75 Years
Genders Eligible for Study